--- title: "BioRestorative Therapies (BRTX) news: reverse split" url: "https://aibio.space/companies/biorestorative-therapies/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BRTX reverse split and Nasdaq notice news: BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split. BioRestorative Therapies, Inc." --- BRTX BioRestorative Therapies, Inc. NASDAQ · United States # BioRestorative Therapies (BRTX) news BRTX reverse split and Nasdaq notice news Company Updates · 2026-10-07 ## [BioRestorative appoints Donald J. Currie to its board](https://aibio.space/news/biorestorative-appoints-donald-j-currie-board/) The board appointed Donald J. Currie as a Class I director on October 7, 2026 to fill the seat left by Katharyn Field, and named him to two committees. ## Latest BioRestorative Therapies news 1. 2026-09-04 Company Updates [BioRestorative's R&D vice president resigns and claims severance](https://aibio.space/news/biorestoratives-r-d-vice-president-resigns-claims-severance/) The company's board does not accept that the resignation was for good reason. The notice seeks about $1.29 million in cash severance under a disputed agreement. 2. 2026-09-02 Listings [BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split](https://aibio.space/news/biorestorative-gets-nasdaq-late-filing-notice-then-does-1-20-reverse/) Nasdaq flagged a missing June-quarter 10-Q on Aug. 21. Days later the company announced a reverse split that cut its shares outstanding to about 1.38 million to fix a separate bid-price shortfall. 3. 2026-08-07 Company Updates [BioRestorative suspends orders and shipments of two biocosmeceutical lines](https://aibio.space/news/biorestorative-suspends-orders-shipments-two-biocosmeceutical-lines/) The company paused its ExoCR and BioX products on August 7, 2026 while it reviews documentation, sourcing and regulatory status. It has not decided to discontinue them. 4. 2026-07-08 Company Updates [BioRestorative's CEO and CFO resign and claim severance; a new CEO is named](https://aibio.space/news/biorestoratives-ceo-cfo-resign-claim-severance-new-ceo-named/) Two executives gave notice on July 13, 2026 and asserted about $2.85 million in aggregate cash severance. The board does not accept the claims, and it named Katharyn Field chief executive officer. 5. 2026-06-10 Debt Financing [BioRestorative sets up $1,000,000 revolving loan from Bowery Group](https://aibio.space/news/biorestorative-sets-up-1-000-000-revolving-loan-bowery-group/) BioRestorative Therapies can borrow up to $1,000,000 from Bowery Group LLC at 12%, and the same agreement brought three director resignations and three new directors designated by the lender. Its cash use in 2025 was $10.8 million. 6. 2026-05-27 Company Updates [BioRestorative files Lance Alstodt's employment agreement terms](https://aibio.space/news/biorestorative-files-lance-alstodts-employment-agreement-terms/) The agreement, dated May 27, 2026, sets a three-year initial term and a bonus of up to 50% of salary. Severance equals two times salary plus bonus if he is terminated without cause or resigns for good reason. ## BioRestorative Therapies at a glance - **Ticker**: BRTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Mar 31, 2026**: $3.6 million ### Related companies - [Citius Pharmaceuticals](https://aibio.space/companies/citius-pharmaceuticals/) NASDAQ: CTXR - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) NASDAQ: ORGO - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Anika Therapeutics](https://aibio.space/companies/anika-therapeutics/) NASDAQ: ANIK - [Celcuity](https://aibio.space/companies/celcuity/) NASDAQ: CELC - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [Cardiff Oncology](https://aibio.space/companies/cardiff-oncology/) NASDAQ: CRDF - [Nutriband](https://aibio.space/companies/nutriband/) NASDAQ: NTRB ### Also on NASDAQ - [908 Devices](https://aibio.space/companies/908-devices/) MASS - [AETHLON MEDICAL INC](https://aibio.space/companies/aethlon-medical/) AEMD - [Monte Rosa Therapeutics](https://aibio.space/companies/monte-rosa-therapeutics/) GLUE - [Celularity](https://aibio.space/companies/celularity/) CELU - [MoonLake Immunotherapeutics](https://aibio.space/companies/moonlake-immunotherapeutics/) MLTX - [Kardigan](https://aibio.space/companies/kardigan/) KARD ## What BioRestorative Therapies does BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Its lead program is the Disc/Spine Program, whose initial investigational product, BRTX-100, is made from a patient's own cultured mesenchymal stem cells collected from bone marrow and injected into a damaged disc for the non-surgical treatment of painful lumbosacral disc disorders. BRTX-100 is in a Phase 2 clinical trial for chronic lower back pain from degenerative disc disease. The FDA cleared an IND for the product for chronic cervical discogenic pain, and granted Fast Track designation for chronic lumbar disc disease. The ThermoStem Program is a preclinical metabolic program using brown adipose derived stem cells and their exosomes to target obesity, type 2 diabetes and related disorders. The company also operates a commercial biocosmeceutical business whose cell-based secretome serum is engineered to reduce the appearance of fine lines and wrinkles. In February 2026 the company reported completing enrollment of 99 patients in its Phase 2 trial. | Product or program | What it is | Stage | |---|---|---| | BRTX-100 | Patient-derived mesenchymal stem cell product injected into degenerative discs | Phase 2 trial for chronic lower back pain; IND cleared for cervical discogenic pain | | ThermoStem Program | Brown adipose derived stem cells and exosomes for obesity and metabolic disorders | pre-clinical | | Biocosmeceutical serum | Cell-based secretome serum for fine lines and wrinkles | commercial | Summarised from the company's [10-K filed Mar 26, 2026](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/form10-k.htm). ## BioRestorative Therapies annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$10.1 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | [$6.7 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | | Net income (loss) | [-$14.2 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | [-$9.0 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | | Cash from operations | [-$10.8 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | | Cash and equivalents | [$1.5 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226023126/) | [$547,890](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | | Short-term investments | [$1.4 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226023126/) | [$10.2 million](https://www.sec.gov/Archives/edgar/data/1505497/000149315226012925/) | Latest balance sheet, Mar 31, 2026 (10-Q): cash and equivalents $3.1 million, plus short-term investments of $479,351, $3.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BioRestorative Therapies Did BioRestorative Therapies do a reverse stock split? Our latest story on this, dated Sep 2, 2026: "BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biorestorative-gets-nasdaq-late-filing-notice-then-does-1-20-reverse/). Has BioRestorative Therapies received a Nasdaq deficiency notice? Our latest story on this, dated Sep 2, 2026: "BioRestorative gets Nasdaq late-filing notice, then does a 1-for-20 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biorestorative-gets-nasdaq-late-filing-notice-then-does-1-20-reverse/). What is the ticker symbol of BioRestorative Therapies? BioRestorative Therapies, Inc. trades under the ticker BRTX on NASDAQ. Where is BioRestorative Therapies listed? BioRestorative Therapies, Inc. is listed on NASDAQ. What is the SEC CIK of BioRestorative Therapies? The SEC Central Index Key (CIK) for BioRestorative Therapies, Inc. is 1505497. Its filings are on SEC EDGAR. How many shares does BioRestorative Therapies have outstanding? 25,478,170 shares as of 2026-05-14, per the cover page of its 10-Q filed 2026-05-14. Which country or territory is BioRestorative Therapies listed under? Our directory records BioRestorative Therapies, Inc. under United States. What does BioRestorative Therapies do? Our directory classifies BioRestorative Therapies, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of BioRestorative Therapies? The ISIN recorded for BioRestorative Therapies, Inc. is US0906557055. Does aibio.space cover BioRestorative Therapies? aibio.space lists BioRestorative Therapies, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is BioRestorative Therapies incorporated? SEC records list its state or country of incorporation as NV. What does BioRestorative Therapies develop? BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Its lead program is the Disc/Spine Program, whose initial investigational product, BRTX-100, is made from a patient's own cultured mesenchymal stem cells collected from bone marrow and injected into a damaged disc for the non-surgical treatment of painful lumbosacral disc disorders. What is BRTX-100 from BioRestorative Therapies? BRTX-100: Patient-derived mesenchymal stem cell product injected into degenerative discs Stage: Phase 2 trial for chronic lower back pain; IND cleared for cervical discogenic pain. What is ThermoStem Program from BioRestorative Therapies? ThermoStem Program: Brown adipose derived stem cells and exosomes for obesity and metabolic disorders Stage: pre-clinical. Is BioRestorative Therapies profitable? BioRestorative Therapies, Inc. reported a net loss of $14.2 million for the fiscal year ended Dec 31, 2025, and used $10.8 million of cash in operations, per its annual report to the SEC. ## Investor discussion: BioRestorative Therapies Members talk about BioRestorative Therapies (BRTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BioRestorative Therapies, newest first. Each line links the filing it comes from. 1. 2026-09-02 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/ea0304309-8k_biore.htm) 2. 2026-09-02 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1505497/000121390026096810/ea030438901ex99-1.htm) 3. 2026-08-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1505497/000121390026093566/ea0303388-8k_biorestorative.htm) 4. 2026-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1505497/000149315226038425/formnt10-q.htm) 5. 2026-05-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1505497/000102177126000084/ex99_1.htm) 6. 2026-02-09 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1505497/000149315226005827/forms-1.htm) 7. 2025-11-18 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1505497/000149315225024081/forms-1.htm) 8. 2025-04-21 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1505497/000102177125000074/brt42125.htm) 9. 2025-03-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1505497/000164117225001011/form10-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BRTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-BRTX/). ## SEC filings and registration - **SEC name**: BioRestorative Therapies, Inc. - **CIK**: 1505497 - **Industry (SIC)**: Services-Misc Health & Allied Services, NEC (8090) - **US tickers**: BRTX (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 40 MARCUS DRIVE, MELVILLE, NY - **Phone**: (631) 760-8100 - **Shares outstanding**: 25,478,170 as of 2026-05-14 (10-Q filed 2026-05-14) - **Former names**: Stem Cell Assurance, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000121390026108467/ea0305784-8k_biore.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000121390026099018/ea0305246-8k_biore.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000121390026096810/ea0304389-8k_biore.htm) filed 2026-09-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000121390026096337/ea0304309-8k_biore.htm) filed 2026-09-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000121390026093566/ea0303388-8k_biorestorative.htm) filed 2026-08-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000149315226038391/form8-k.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000149315226033593/form8-k.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1505497/000102177126000093/brtx-20260612.htm) filed 2026-06-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001505497), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details BioRestorative Therapies, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BRTX, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BioRestorative Therapies, Inc. - **Ticker**: BRTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US0906557055 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BRTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biorestorative-therapies/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioRestorative Therapies (BRTX) news: reverse split", 2026-10-31, https://aibio.space/companies/biorestorative-therapies/